We assessed the performance of a 4-kallikrein panel with and without microseminoprotein-b to predict high grade (Gleason 7þ/Gleason Grade Group 2þ) prostate cancer on biopsy in a multiethnic cohort from PLCO (Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial). Materials and Methods: Levels of free, intact, total prostate specific antigen, human kallikrein-2 and microseminoprotein-b were measured while blinded to outcomes in cryopreserved serum from men in the intervention arm of PLCO. Marker levels of 946 men, of whom 100 were African American, were incorporated into a prespecified statistical model to predict high grade prostate cancer on biopsy. Results: The detection of high grade prostate cancer in 94 men (10%) was enhanced by the 4-kallikrein panel with an AUC of 0.79 compared to 0.73 for PCPTRC (Prostate Cancer Prevention Trial Risk Calculator), representing a 0.060 increase (95% CI 0.032e0.088, p <0.01). Additionally, the AUC increased from 0.79 to 0.81 when microseminoprotein-b was added to the 4-kallikrein panel. In African American men, the 4-kallikrein panel model also enhanced high grade prostate cancer detection over that of prostate specific antigen (AUC 0.80 vs 0.67). As an illustration of clinical implications, using 1 cutoff point for biopsy (6% risk of high grade prostate cancer) with the 4-kallikrein panel model would have eliminated unnecessary biopsies in 420 per 1,000 men (42%) while detecting high grade prostate cancer in 83 of 93 (88%).
OVER the last 20 years, PSA has been applied as a screening tool for PCa. Although PSA provides a significant benefit over DRE alone and it is associated with clinically significant PCa, 1 moderately elevated PSA has poor specificity and positive predictive value. For instance, the rate of positive biopsy was 24% in ERSPCS (European Randomized Study of Prostate Cancer Screening) and 35% in PLCO. 2, 3 Furthermore, less than a third of those men with positive biopsy have clinically aggressive disease that requires consideration for curative intervention. 4 A series of retrospective cohort studies have investigated a multivariable model that combines 4 kallikrein marker levels in blood (total PSA, free PSA, intact PSA and hK2) with clinical characteristics (age, DRE and history of prior negative biopsy). The 4K panel demonstrated improved risk discrimination compared to PSA and clinical characteristics alone. Decision analyses have demonstrated that using the panel would reduce the number of biopsies performed, while missing few high grade cases. 5e9 The accuracy of the 4K panel to predict aggressive disease on radical prostatectomy has also been demonstrated. 10 Although it has been studied and validated in European populations, 5e10 the 4K panel has not been extensively evaluated in men in the United States. 11 More importantly, as the European population was almost exclusively Caucasian, the performance characteristics of the 4K panel need to be studied in African American men, who more often present with advanced and aggressive disease, and are more likely to die of PCa. 12, 13 We examined a prespecified prediction model using the 4K panel to diagnose high grade PCa using preserved serum samples of men from the PLCO screening trial, who underwent biopsy for elevated PSA (4.0 ng/ml or greater). As a secondary aim, we examined the benefit of another candidate blood biomarker, MSP, 14 in combination with the 4K panel.
MATERIALS AND METHODS

Study Cohort
With institutional review board approval from all study centers, we received prebiopsy patient serum samples from the PLCO biorepository and assayed the levels of the 4 kallikrein markers (free PSA, intact PSA, total PSA and hK2) as well as MSP. The 4K panel was combined with various clinical parameters in a prespecified statistical model. Biopsy results were released to the study statisticians only after predictions were submitted to a third party. Accordingly, assays, modeling and outcome were assessed independently and blindly.
Our study cohort included patients from the intervention arm of PLCO, who provided consent, had no prior history of cancer, underwent no biopsies prior to randomization, were younger than 75 years, and had PSA 4 ng/ml or greater during the biopsy year, a documented Gleason score on biopsy and serum from the biopsy year available in the biorepository. In PLCO, a positive screening result (suspicious DRE or PSA 4 ng/ml or greater) in the intervention arm resulted in a notification to the patient primary care physician, who determined the subsequent diagnostic evaluation. 3 The biopsy Gleason score was obtained by PLCO trial staff and collected by medical data abstractors. No central pathological review was performed.
All samples from the 113 eligible African American nonHispanic men were included and 887 samples were selected randomly from the remaining eligible men to build our study cohort of 1,000. The 54 patients with missing data were excluded from further analysis, leaving a final sample of 946, of whom 100 were nonHispanic African American men. 19 The intact PSA assay measures only single chain intact forms of free PSA since the monoclonal 4D4 IgG used in this assay does not bind multichain forms of free PSA cleaved at Lys 145 or Lys 146 . Production and purification of the polyclonal rabbit antiMSP antibody, protocols for biotinylation and Europium labeling of the antiMSP antibody, and performance of the MSP immunoassay were performed as previously reported.
Laboratory Methods
14 All assay measurements were done while blinded to biopsy results.
Predictive Models
We assessed the accuracy of models to predict prostate biopsy outcome among men in our study cohort. Primarily we were interested in the accuracy of a model utilizing age, the 4K panel and DRE to predict high grade cancer on biopsy. Gleason score 7 or greater, or GGG 20 2 or greater were considered high grade PCa. To assess the added clinical utility of the 4K panel, we compared these results to a model based on age, total PSA and DRE as well as PCPTRC. 21 Additional predictive models that included various combinations of the clinical variables (age, PSA, DRE and the 4K panel) as well as MSP were examined. All models were prespecified other than those testing the value of incorporating MSP. The 4K and PSA models were derived from the Rotterdam section of ERSPCS. 6 
Statistical Methods
The discrimination of the predictive models was assessed using ROC curves and AUC calculations. The calibration of the models was also assessed visually by plotting the predicted risk against the observed risk of PCa. A perfectly calibrated model would have predicted risk and shown a fall in risk along a 45-degree line, indicating that the risk obtained from the model reflected the actual observed risk of PCa on biopsy. Decision curve analysis was used to assess the clinical impact of the models. 22 Due to the study sampling scheme with the intended oversampling of African American patients, all cohort level statistics (eg AUC, calibration, decision curve analysis and clinical consequences) were weighted to represent the original PLCO cohort. Differences in discrimination were calculated and CIs of the difference were estimated using clustered bootstrap resampling.
Analyses were then repeated separately for African American men and for men of other races to assess differences in the performance of the model by race. As differences in prostate biopsy outcomes were observed between African American men and men of other races, the models were refit to include race as a covariate. Constrained logistic regression was used to assess the magnitude of the adjustment to the risk prediction required for African American men. Race and the risk prediction were entered into the regression model. Model risk was entered on the inverse logit scale and the coefficient was constrained to be 1.
Logistic regression was also done to assess whether MSP would improve the performance of the models including the kallikrein makers. Tenfold cross validation was used when assessing the performance of the model including MSP to account for the fact that models were built and evaluated on the same data set. All analyses were performed with StataÒ, version 13.0. However, the CIs of the differences in AUC by race were not statistically significant (95% CI À0.10e0.13). Figure 1 shows the calibration plot of the 4K model with and without DRE. The calibration plot demonstrated good agreement for patients with an estimated 20% or less risk of high grade PCa. Figure 2 shows the decision curve analysis for the 4K model with and without MSP. The decision curve analysis revealed improved clinical outcomes over biopsy all or no biopsy across the range of reasonable threshold probabilities for high grade PCa. Table 3 shows the clinical performance of using these models at various risk thresholds to perform biopsy compared to PSA alone. At 1 illustrative threshold (a 6% risk of high grade disease), using the panel in 1,000 men would reduce the number of biopsies by 420 and the number of low grade PCa diagnoses by 64. Of the 420 men avoiding biopsy, 11 (2.6%) would harbor high grade disease. 
RESULTS
DISCUSSION
In our study of the 4K panel in participants from the intervention arm of PLCO, we found that a prespecified 4K panel model improved predictive discrimination for high grade PCa compared to other clinical risk determinants (age, PSA, DRE and PCPTRC). Calibration was generally good and decision curve analysis demonstrated that the 4K panel would improve clinical outcomes compared to biopsy in all men. As such, using the 4K panel to determine the biopsy indication would importantly decrease the number of biopsies performed, while missing few high grade PCa cases.
Because our study cohort was generated from the PLCO trial, the study results are constrained to the inclusion and exclusion criteria of the original trial. Specifically, the improved risk discrimination demonstrated with use of the 4K panel model cannot necessarily be applied to men older than 74 years, those with PSA less than 4 ng/ml or those who underwent prior biopsy. Given the questionable benefit of PCa screening, diagnosis or treatment in older men, 23 the most clinically relevant limitation listed above is the inability to apply our study results to men with prior biopsy. In these men, particularly those with prior negative biopsies, adjuvant diagnostic tests such as magnetic resonance imaging may be necessary to improve risk stratification and decrease unnecessary subsequent biopsies.
The 4K panel provided a slightly greater improvement in risk discrimination for African American men compared to men of other races (AUC 0.803 vs 0.781). In common with other studies, African American race was found to be a significant predictor of high grade PCa independent of the 4K panel. Although we were unable to determine whether the 4K panel is significantly superior in African American men compared to men of other races, an analysis for which we had limited power, our finding suggests that improvements provided by the 4K panel are highly unlikely to be worse in this racial group.
MSP was found to improve discrimination when added to the 4K panel. Decision analysis illustrated a small improvement in clinical outcome when using MSP with the 4K panel compared to the 4K panel alone. An extension of this concept was found in the Stockholm 3 study. 24 In prospective fashion, Gr€ onberg et al used a combination of serum biomarkers (of which 5 of 6 are the same as those used in the current study but measured on a different instrument platform), single nucleotide The risk discrimination in our study was similar to that of a prospective study of a commercialized 4K based model (4KscoreÒ) that was applied in American men accrued in routine urological practice (AUC 0.82, 95% CI 0.79e0.85). 25 The improvement in risk discrimination for high grade PCa over commonly used clinical tools (eg PSA and PCPTRC) was also similar in both studies. There is also similarity in findings with respect to race with both studies showing that the discrimination of the 4K panel was higher in African American men compared to other races, although the limited number of African American men in the 2 studies prevents a definitive conclusion. The key result in each case is that the 4K model significantly improved high grade PCa risk discrimination in a multiethnic population in the United States, confirming the initial European results despite differences in racial composition.
Given the current controversy of PCa screening, and associated over diagnosis and overtreatment, 23 the need for clinical tools to provide improved risk stratification prior to prostate biopsy, particularly for high grade PCa, 26 is critical to improve PCa care in the United States. The results of this study confirm that the 4K panel can serve as such a tool to decrease the number of biopsies performed while minimizing high grade PCa that would be delayed or missed. A reduction in the prostate biopsies performed and, thus, a reduction in the diagnosis of low grade PCa with minimal sacrifices in the detection of high grade PCa would likely provide a net positive impact on total health care costs as well as patient morbidity. 27, 28 Future studies must consider the costs associated with using each additional biomarker (eg MSP), the comparative effectiveness of magnetic resonance imaging as a risk stratification tool over biomarkers 29 and the optimal cost-effective strategy for timing these tests before biopsy.
This study is not without limitations. As discussed above, the study results may not clearly be applied to men who are older than 74 years, those with PSA less than 4 ng/ml or those who have undergone prior biopsy. Our study cohort was built to oversample African American participants in PLCO and approached the most recent United States racial demographics (12.6% of the American population on the most recent census identified as African American). 30 However, the study was likely underpowered to detect a significant difference in risk discrimination using the 4K panel in African American men over men of other races. The overall incidence of high grade PCa in our study was lower Numbers are presented per 1,000 men screened in PLCO cohort. * Gleason score 7 or greater (GGG 2 or greater). than in some contemporary studies. As a result, the 4K panel overestimated the high grade PCa risk at higher clinical risk thresholds (greater than 20%, fig. 1 ). This is likely less clinically meaningful since men at substantially high clinical risk do not represent the majority of the screened population. Furthermore, these patients would be recommended for biopsy whether the risk of high grade PCa was 40% based on PSA or 60% with the 4K panel model.
CONCLUSIONS
Using the 4K panel in a select population of PLCO participants confirmed the results of prior studies that the 4K panel can improve the detection of high grade PCa in a multiethnic cohort in the United States. Furthermore, the improvement in risk discrimination was similar among African American men. Finally, the addition of a fifth serum biomarker, MSP, provided an incremental improvement in the ability to identify patients with high grade PCa.
